Optimal design of clinical trials with computer simulation based on results of earlier trials, illustrated with a lipodystrophy trial in HIV patients
暂无分享,去创建一个
Tony Greenfield | Josep Casanovas | Ismail Abbas | Joan Rovira | J. Casanovas | J. Rovira | I. Abbas | Tony Greenfield
[1] R. Paredes,et al. Virological, immunological, and clinical impact of switching from protease inhibitors to nevirapine or to efavirenz in patients with human immunodeficiency virus infection and long-lasting viral suppression. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[2] D. Warner,et al. Statistical power, sample size, and their reporting in randomized controlled trials , 1995 .
[3] Yasuo Ohashi,et al. Statistical comparison of random allocation methods in cancer clinical trials. , 2004, Controlled clinical trials.
[4] B. Clotet,et al. Cumulative risk for developing hyperlipidemia in HIV-infected patients treated with protease inhibitors , 1999 .
[5] Douglas G Altman,et al. Treatment allocation by minimisation , 2005, BMJ : British Medical Journal.
[6] Wayne Ewy,et al. Application of Clinical Trial Simulation to Compare Proof-of-Concept Study Designs for Drugs with a Slow Onset of Effect; An Example in Alzheimer's Disease , 2006, Pharmaceutical Research.
[7] K. Carroll,et al. Optimizing randomized phase II trials assessing tumor progression. , 2007, Contemporary clinical trials.
[8] Josep Casanovas,et al. Validation by simulation of a clinical trial model using the standardized mean and variance criteria , 2006, J. Biomed. Informatics.
[9] A. Kirby,et al. Sample size estimation using repeated measurements on biomarkers as outcomes. , 1994, Controlled clinical trials.
[10] E. Eisenhauer,et al. Phase I and II trials of novel anti-cancer agents: endpoints, efficacy and existentialism. The Michel Clavel Lecture, held at the 10th NCI-EORTC Conference on New Drugs in Cancer Therapy, Amsterdam, 16-19 June 1998. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.
[11] J M Lachin,et al. Statistical considerations in the intent-to-treat principle. , 2000, Controlled clinical trials.
[12] D. DeMets,et al. Surrogate End Points in Clinical Trials: Are We Being Misled? , 1996, Annals of Internal Medicine.
[13] Scott Tonidandel,et al. Sample size and power calculations in repeated measurement analysis , 2001, Comput. Methods Programs Biomed..
[14] R. Kronmal,et al. Improving the estimation of change from baseline in a continuous outcome measure in the clinical trial setting. , 2005, Contemporary clinical trials.